This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

J.C. Penney Gets $1.75B Loan Commitment: Ahead of the Ticker

NEW YORK ( TheStreet) -- Struggling retailer J.C. Penney (JCP - Get Report) received a $1.75 billion term loan commitment from Goldman Sachs (GS - Get Report).

J.C. Penney said in a statement that the five-year loan will be backed by the department store chain's real estate and other assets. The company plans to release more terms of the loan in a filing with the Securities and Exchange Commission.

The company, which is trying to shore up capital and revamp its financial situation, also recently borrowed $850 million from its $1.85 billion revolving credit facility.

Under former CEO Ron Johnson, J.C. Penney endured a 25% decline in sales last year as Johnson tried a more upscale, "no sales or coupons" strategy. He has been replaced by Myron Ullman, who is taking the helm of J.C. Penney once again and is expected to return to the company's former strategy of discount pricing.

The new financing comes on top of the recent announcement that billionaire investor George Soros took a 7.9% stake in the company.

Chinese e-commerce company Alibaba Group has purchased an 18% stake in Sina's (SINA - Get Report) microblogging service Weibo for $586 million.

The deal values Weibo at more than $3 billion.

Sina said the deal should generate $380 million in revenue for Weibo in the next three years, aiding the company in its quest to make the service more profitable.

Sina's U.S.-listed shares climbed 17% to $58.85 on the news.

Alibaba will also receive the option to buy up to 30% of Weibo within a stipulated amount of time as part of the agreement. According to Sina, Alibaba and Weibo will work together on things like data exchange, online payments and marketing.

Yahoo (YHOO - Get Report) owns 23% of Alibaba Group.

Drugmakers Pfizer (PFE - Get Report) and Merck (MRK - Get Report) said they are embarking on the joint development of Pfizer's experimental type 2 diabetes drug, ertugliflozin.

The companies expect late-stage trials of the drug to start later this year. Pfizer has received $60 million in upfront payment and milestones so far and will be eligible for more payments based on certain clinical, regulatory and commercial achievements. Merck and Pfizer will share potential revenue and specific costs on a 60/40 percent basis.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BMY $72.18 0.00%
GS $164.11 0.00%
JCP $9.28 0.00%
MRK $54.84 0.00%
PFE $32.71 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs